Showing results (191-200 of 248) with videos related to

Sort By:
Pageof 25
Lancet (London, England)|May 10, 2026
Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trialEric F Morand, Maria Dall'Era, Jorge Sanchez-Guerrero, et al.
Lupus Science & Medicine|December 20, 2023
Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signatureLaurent Arnaud, Richard Furie, Eric F Morand, et al.
Advances in Therapy|September 8, 2025
Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus ErythematosusCristina Arriens, Eric F Morand, Anca D Askanase, et al.
Nucleic Acids Research|June 12, 2012
A miR-19 regulon that controls NF-κB signalingMichael P Gantier, H James Stunden, Claire E McCoy, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2022
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusKenneth C Kalunian, Richard Furie, Eric F Morand, et al.
The Lancet. Rheumatology|July 6, 2024
Systemic lupus erythematosus in Aboriginal and Torres Strait Islander peoples in Australia: addressing disparities and barriers to optimising patient careLaura E Eades, Alberta Y Hoi, Ruaidhri Liddle, et al.
Lupus Science & Medicine|August 3, 2023
Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspectiveJoy Buie, Lauren Bloch, Eric F Morand, et al.
Plos One|June 29, 2018
Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patientsCristina M Lanata, Joanne Nititham, Kimberly E Taylor, et al.
Lancet (London, England)|February 27, 2023
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)Eric F Morand, Edward M Vital, Michelle Petri, et al.
Lancet (London, England)|February 27, 2023
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)Michelle Petri, Ian N Bruce, Thomas Dörner, et al.
Pageof 25